[
  {
    "title": "Thomas C. S\u00fcdhof",
    "text": "Introduction\nThomas Christian Sudhof (German pronunciation: ['to:mas 'zy:t,ho:f] i; born December 22, 1955), ForMemRS, is a German-American biochemist known for his study of synaptic transmission. Currently, he is a professor in the school of medicine in the department of molecular and cellular physiology, and by courtesy in neurology, and in psychiatry and behavioral sciences at Stanford University.",
    "university": "Stanford University",
    "is_supporting": true,
    "idx": 0,
    "question_id": "case_study_university/question_1.json",
    "paragraph_text": "Introduction\nThomas Christian Sudhof (German pronunciation: ['to:mas 'zy:t,ho:f] i; born December 22, 1955), ForMemRS, is a German-American biochemist known for his study of synaptic transmission. Currently, he is a professor in the school of medicine in the department of molecular and cellular physiology, and by courtesy in neurology, and in psychiatry and behavioral sciences at Stanford University."
  },
  {
    "title": "Thomas C. S\u00fcdhof",
    "text": "Career and research\nSudhof's research has not only given the scientific community a great understanding of the processes underlying synaptic transmission and synapse formation, but has also advanced medical knowledge of mechanisms behind poorly understood diseases such as Alzheimer's, Schizophrenia, and Autism. He is currently working with a diverse group of researchers at the Howard Hughes Medical Institute to develop mouse models for mutants of synaptic genes.",
    "university": "Stanford University",
    "is_supporting": true,
    "idx": 1,
    "question_id": "case_study_university/question_1.json",
    "paragraph_text": "Career and research\nSudhof's research has not only given the scientific community a great understanding of the processes underlying synaptic transmission and synapse formation, but has also advanced medical knowledge of mechanisms behind poorly understood diseases such as Alzheimer's, Schizophrenia, and Autism. He is currently working with a diverse group of researchers at the Howard Hughes Medical Institute to develop mouse models for mutants of synaptic genes."
  },
  {
    "title": "Robert Malenka",
    "text": "Introduction\nRobert C. Malenka (born June 21, 1955) is a Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University. He is also the director of the Nancy Friend Pritzker Laboratory in the Stanford Medical Center.",
    "university": "Stanford University",
    "is_supporting": true,
    "idx": 2,
    "question_id": "case_study_university/question_1.json",
    "paragraph_text": "Introduction\nRobert C. Malenka (born June 21, 1955) is a Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University. He is also the director of the Nancy Friend Pritzker Laboratory in the Stanford Medical Center."
  },
  {
    "title": "Robert Malenka",
    "text": "Introduction\n[1]  He is a member of the National Academies of Sciences, Engineering, and Medicine, as well as the American Academy of Arts and Sciences. [2] Malenka's laboratory research with the National Alzheimer's Foundation has informed researchers aiming to find a neuronal basis for Alzheimer's disease.",
    "university": "Stanford University",
    "is_supporting": true,
    "idx": 3,
    "question_id": "case_study_university/question_1.json",
    "paragraph_text": "Introduction\n[1]  He is a member of the National Academies of Sciences, Engineering, and Medicine, as well as the American Academy of Arts and Sciences. [2] Malenka's laboratory research with the National Alzheimer's Foundation has informed researchers aiming to find a neuronal basis for Alzheimer's disease."
  },
  {
    "title": "David Eagleman",
    "content": "Introduction\nDavid Eagleman (born April 25, 1971) is an American neuroscientist, author, and science communicator. He teaches neuroscience at Stanford University[1] and is CEO and co-founder of Neosensory, a company that develops devices for sensory substitution. [2] He also directs the non-profit Center for Science and Law, which seeks to align the legal system with modern neuroscience[3] and is Chief Science Officer and co-founder of BrainCheck, a digital cognitive health platform used in medical practices and health systems.",
    "is_supporting": false,
    "idx": 4,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nDavid Eagleman (born April 25, 1971) is an American neuroscientist, author, and science communicator. He teaches neuroscience at Stanford University[1] and is CEO and co-founder of Neosensory, a company that develops devices for sensory substitution. [2] He also directs the non-profit Center for Science and Law, which seeks to align the legal system with modern neuroscience[3] and is Chief Science Officer and co-founder of BrainCheck, a digital cognitive health platform used in medical practices and health systems.",
    "paragraph_text": "Introduction\nDavid Eagleman (born April 25, 1971) is an American neuroscientist, author, and science communicator. He teaches neuroscience at Stanford University[1] and is CEO and co-founder of Neosensory, a company that develops devices for sensory substitution. [2] He also directs the non-profit Center for Science and Law, which seeks to align the legal system with modern neuroscience[3] and is Chief Science Officer and co-founder of BrainCheck, a digital cognitive health platform used in medical practices and health systems."
  },
  {
    "title": "Brian Kobilka",
    "content": "Introduction\nBrian Kent Kobilka (born May 30, 1955)[1] is an American physiologist and a recipient of the 2012 Nobel Prize in Chemistry with Robert Lefkowitz for discoveries that reveal the workings of G protein-coupled receptors. He is currently a professor in the department of Molecular and Cellular Physiology at Stanford University School of Medicine.",
    "is_supporting": false,
    "idx": 5,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nBrian Kent Kobilka (born May 30, 1955)[1] is an American physiologist and a recipient of the 2012 Nobel Prize in Chemistry with Robert Lefkowitz for discoveries that reveal the workings of G protein-coupled receptors. He is currently a professor in the department of Molecular and Cellular Physiology at Stanford University School of Medicine.",
    "paragraph_text": "Introduction\nBrian Kent Kobilka (born May 30, 1955)[1] is an American physiologist and a recipient of the 2012 Nobel Prize in Chemistry with Robert Lefkowitz for discoveries that reveal the workings of G protein-coupled receptors. He is currently a professor in the department of Molecular and Cellular Physiology at Stanford University School of Medicine."
  },
  {
    "title": "Karl Deisseroth",
    "content": "Introduction\nKarl Alexander Deisseroth (born November 18, 1971) is an American scientist. He is the D.H. Chen Foundation Professor of Bioengineering and of psychiatry and behavioral sciences at Stanford University. He is known for creating and developing the technologies of hydrogel-tissue chemistry (e.g., CLARITY, STARmap) and optogenetics, and for applying integrated optical and genetic strategies to study normal neural circuit function, as well as dysfunction in neurological and psychiatric disease.",
    "is_supporting": false,
    "idx": 6,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nKarl Alexander Deisseroth (born November 18, 1971) is an American scientist. He is the D.H. Chen Foundation Professor of Bioengineering and of psychiatry and behavioral sciences at Stanford University. He is known for creating and developing the technologies of hydrogel-tissue chemistry (e.g., CLARITY, STARmap) and optogenetics, and for applying integrated optical and genetic strategies to study normal neural circuit function, as well as dysfunction in neurological and psychiatric disease.",
    "paragraph_text": "Introduction\nKarl Alexander Deisseroth (born November 18, 1971) is an American scientist. He is the D.H. Chen Foundation Professor of Bioengineering and of psychiatry and behavioral sciences at Stanford University. He is known for creating and developing the technologies of hydrogel-tissue chemistry (e.g., CLARITY, STARmap) and optogenetics, and for applying integrated optical and genetic strategies to study normal neural circuit function, as well as dysfunction in neurological and psychiatric disease."
  },
  {
    "title": "Eric I. Knudsen",
    "content": "Introduction\nEric Knudsen is a professor of neurobiology at Stanford University. He is best known for his discovery, along with Masakazu Konishi, of a brain map of sound location in two dimensions in the barn owl, tyto alba.",
    "is_supporting": false,
    "idx": 7,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nEric Knudsen is a professor of neurobiology at Stanford University. He is best known for his discovery, along with Masakazu Konishi, of a brain map of sound location in two dimensions in the barn owl, tyto alba.",
    "paragraph_text": "Introduction\nEric Knudsen is a professor of neurobiology at Stanford University. He is best known for his discovery, along with Masakazu Konishi, of a brain map of sound location in two dimensions in the barn owl, tyto alba."
  },
  {
    "title": "Tina Seelig",
    "content": "Introduction\nTina Lynn Seelig (born 1957)[1] is an American educator, entrepreneur, and author of several books on creativity and innovation. She is a faculty member at Stanford University.",
    "is_supporting": false,
    "idx": 8,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nTina Lynn Seelig (born 1957)[1] is an American educator, entrepreneur, and author of several books on creativity and innovation. She is a faculty member at Stanford University.",
    "paragraph_text": "Introduction\nTina Lynn Seelig (born 1957)[1] is an American educator, entrepreneur, and author of several books on creativity and innovation. She is a faculty member at Stanford University."
  },
  {
    "title": "Russell A. Poldrack",
    "content": "Introduction\nRussell \"Russ\" Alan Poldrack (born 1967) is an American psychologist and neuroscientist. He is a professor of psychology at Stanford University, associate director of Stanford Data Science, member of the Stanford Neuroscience Institute[1] and director of the Stanford Center for Reproducible Neuroscience[2] and the SDS Center for Open and Reproducible Science.",
    "is_supporting": false,
    "idx": 9,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nRussell \"Russ\" Alan Poldrack (born 1967) is an American psychologist and neuroscientist. He is a professor of psychology at Stanford University, associate director of Stanford Data Science, member of the Stanford Neuroscience Institute[1] and director of the Stanford Center for Reproducible Neuroscience[2] and the SDS Center for Open and Reproducible Science.",
    "paragraph_text": "Introduction\nRussell \"Russ\" Alan Poldrack (born 1967) is an American psychologist and neuroscientist. He is a professor of psychology at Stanford University, associate director of Stanford Data Science, member of the Stanford Neuroscience Institute[1] and director of the Stanford Center for Reproducible Neuroscience[2] and the SDS Center for Open and Reproducible Science."
  },
  {
    "title": "Lisa M. Giocomo",
    "content": "Introduction\nLisa Giocomo is an American neuroscientist who is a Professor in the Department of Neurobiology at Stanford University School of Medicine. Giocomo probes the molecular and cellular mechanisms underlying cortical neural circuits involved in spatial navigation and memory.",
    "is_supporting": false,
    "idx": 10,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nLisa Giocomo is an American neuroscientist who is a Professor in the Department of Neurobiology at Stanford University School of Medicine. Giocomo probes the molecular and cellular mechanisms underlying cortical neural circuits involved in spatial navigation and memory.",
    "paragraph_text": "Introduction\nLisa Giocomo is an American neuroscientist who is a Professor in the Department of Neurobiology at Stanford University School of Medicine. Giocomo probes the molecular and cellular mechanisms underlying cortical neural circuits involved in spatial navigation and memory."
  },
  {
    "title": "Jennifer Dionne",
    "content": "Introduction\nJennifer (Jen) Dionne is an American scientist and pioneer of nanophotonics. She is currently senior associate vice provost of research platforms at Stanford University, a Chan Zuckerberg Biohub Investigator, and an associate professor of materials science and engineering and by courtesy, of radiology. She serves as director of the Department of Energy's \"Photonics at Thermodynamic Limits\" Energy Frontier Research Center (EFRC), which strives to create thermodynamic engines driven by light, and she leads the \"Extreme Scale Characterization\" efforts of the DOE's Q-NEXT Quantum Science Center.",
    "is_supporting": false,
    "idx": 11,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nJennifer (Jen) Dionne is an American scientist and pioneer of nanophotonics. She is currently senior associate vice provost of research platforms at Stanford University, a Chan Zuckerberg Biohub Investigator, and an associate professor of materials science and engineering and by courtesy, of radiology. She serves as director of the Department of Energy's \"Photonics at Thermodynamic Limits\" Energy Frontier Research Center (EFRC), which strives to create thermodynamic engines driven by light, and she leads the \"Extreme Scale Characterization\" efforts of the DOE's Q-NEXT Quantum Science Center.",
    "paragraph_text": "Introduction\nJennifer (Jen) Dionne is an American scientist and pioneer of nanophotonics. She is currently senior associate vice provost of research platforms at Stanford University, a Chan Zuckerberg Biohub Investigator, and an associate professor of materials science and engineering and by courtesy, of radiology. She serves as director of the Department of Energy's \"Photonics at Thermodynamic Limits\" Energy Frontier Research Center (EFRC), which strives to create thermodynamic engines driven by light, and she leads the \"Extreme Scale Characterization\" efforts of the DOE's Q-NEXT Quantum Science Center."
  },
  {
    "title": "Fei-Fei Li",
    "content": "Introduction\nFei-Fei Li (Li Fei Fei ; born 1976) is a China-born American computer scientist, known for establishing ImageNet, the dataset that enabled rapid advances in computer vision in the 2010s. [4][5][6][7] She is Sequoia Capital professor of computer science at Stanford University and former board director at Twitter. [8] Li is a co-director of the Stanford Institute for Human-Centered Artificial Intelligence and a co-director of the Stanford Vision and Learning Lab.",
    "is_supporting": false,
    "idx": 12,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nFei-Fei Li (Li Fei Fei ; born 1976) is a China-born American computer scientist, known for establishing ImageNet, the dataset that enabled rapid advances in computer vision in the 2010s. [4][5][6][7] She is Sequoia Capital professor of computer science at Stanford University and former board director at Twitter. [8] Li is a co-director of the Stanford Institute for Human-Centered Artificial Intelligence and a co-director of the Stanford Vision and Learning Lab.",
    "paragraph_text": "Introduction\nFei-Fei Li (Li Fei Fei ; born 1976) is a China-born American computer scientist, known for establishing ImageNet, the dataset that enabled rapid advances in computer vision in the 2010s. [4][5][6][7] She is Sequoia Capital professor of computer science at Stanford University and former board director at Twitter. [8] Li is a co-director of the Stanford Institute for Human-Centered Artificial Intelligence and a co-director of the Stanford Vision and Learning Lab."
  },
  {
    "title": "Robert Sapolsky",
    "content": "Introduction\nRobert Morris Sapolsky (born April 6, 1957) is an American neuroendocrinology researcher and author. He is a professor of biology, neurology, neurological sciences, and neurosurgery at Stanford University.",
    "is_supporting": false,
    "idx": 13,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nRobert Morris Sapolsky (born April 6, 1957) is an American neuroendocrinology researcher and author. He is a professor of biology, neurology, neurological sciences, and neurosurgery at Stanford University.",
    "paragraph_text": "Introduction\nRobert Morris Sapolsky (born April 6, 1957) is an American neuroendocrinology researcher and author. He is a professor of biology, neurology, neurological sciences, and neurosurgery at Stanford University."
  },
  {
    "title": "Carla J. Shatz",
    "content": "Introduction\nCarla J. Shatz (born 1947) is an American neurobiologist and an elected member of the American Academy of Arts and Sciences,[1] the American Philosophical Society, the National Academy of Sciences,[2] and the National Academy of Medicine. She was the first woman to receive a PhD in neurobiology from Harvard. [3][4] Shatz received a tenured position in the basic sciences at Stanford Medical School and later returned to Harvard to head the university's Department of Neurobiology.",
    "is_supporting": false,
    "idx": 14,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nCarla J. Shatz (born 1947) is an American neurobiologist and an elected member of the American Academy of Arts and Sciences,[1] the American Philosophical Society, the National Academy of Sciences,[2] and the National Academy of Medicine. She was the first woman to receive a PhD in neurobiology from Harvard. [3][4] Shatz received a tenured position in the basic sciences at Stanford Medical School and later returned to Harvard to head the university's Department of Neurobiology.",
    "paragraph_text": "Introduction\nCarla J. Shatz (born 1947) is an American neurobiologist and an elected member of the American Academy of Arts and Sciences,[1] the American Philosophical Society, the National Academy of Sciences,[2] and the National Academy of Medicine. She was the first woman to receive a PhD in neurobiology from Harvard. [3][4] Shatz received a tenured position in the basic sciences at Stanford Medical School and later returned to Harvard to head the university's Department of Neurobiology."
  },
  {
    "title": "Andrea Goldsmith",
    "content": "Introduction\nAndrea Goldsmith FREng [1] is an American electrical engineer and the Dean of Engineering and Applied Science at Princeton University. [2][3][4] She is also the Arthur LeGrand Doty Professor of Electrical Engineering at Princeton. She was previously the Stephen Harris Professor in the School of Engineering at Stanford University,[5] as well as a faculty affiliate at the Stanford Neurosciences Institute.",
    "is_supporting": false,
    "idx": 15,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nAndrea Goldsmith FREng [1] is an American electrical engineer and the Dean of Engineering and Applied Science at Princeton University. [2][3][4] She is also the Arthur LeGrand Doty Professor of Electrical Engineering at Princeton. She was previously the Stephen Harris Professor in the School of Engineering at Stanford University,[5] as well as a faculty affiliate at the Stanford Neurosciences Institute.",
    "paragraph_text": "Introduction\nAndrea Goldsmith FREng [1] is an American electrical engineer and the Dean of Engineering and Applied Science at Princeton University. [2][3][4] She is also the Arthur LeGrand Doty Professor of Electrical Engineering at Princeton. She was previously the Stephen Harris Professor in the School of Engineering at Stanford University,[5] as well as a faculty affiliate at the Stanford Neurosciences Institute."
  },
  {
    "title": "Emmanuel Mignot",
    "content": "Introduction\nEmmanuel Mignot (born 1959 in Paris) is a sleep researcher and director of the Stanford Center for Sleep Sciences and Medicine, at Stanford University. Dr. Mignot is an authority on sleep research and medicine, and is mostly known for his work on narcolepsy.",
    "is_supporting": false,
    "idx": 16,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nEmmanuel Mignot (born 1959 in Paris) is a sleep researcher and director of the Stanford Center for Sleep Sciences and Medicine, at Stanford University. Dr. Mignot is an authority on sleep research and medicine, and is mostly known for his work on narcolepsy.",
    "paragraph_text": "Introduction\nEmmanuel Mignot (born 1959 in Paris) is a sleep researcher and director of the Stanford Center for Sleep Sciences and Medicine, at Stanford University. Dr. Mignot is an authority on sleep research and medicine, and is mostly known for his work on narcolepsy."
  },
  {
    "title": "Subhasish Mitra",
    "content": "Introduction\nSubhasish Mitra is an American Computer Science and Electrical Engineering professor at Stanford University. He directs the Stanford Robust Systems Group, leads the Computation Focus Area of the Stanford SystemX Alliance, and is a member of the Wu Tsai Neurosciences Institute.",
    "is_supporting": false,
    "idx": 17,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nSubhasish Mitra is an American Computer Science and Electrical Engineering professor at Stanford University. He directs the Stanford Robust Systems Group, leads the Computation Focus Area of the Stanford SystemX Alliance, and is a member of the Wu Tsai Neurosciences Institute.",
    "paragraph_text": "Introduction\nSubhasish Mitra is an American Computer Science and Electrical Engineering professor at Stanford University. He directs the Stanford Robust Systems Group, leads the Computation Focus Area of the Stanford SystemX Alliance, and is a member of the Wu Tsai Neurosciences Institute."
  },
  {
    "title": "Henry Greely",
    "content": "Introduction\nHenry T. \"Hank\" Greely is an American lawyer, a leading authority on the ethical, legal, and social implications of new biomedical technologies, particularly those related to genetics, assisted reproduction, neuroscience and stem cell research. [1]  Greely is the Deane F. and Kate Edelman Johnson Professor of Law, the     Director of the Center for Law and the Biosciences, the Genetics Chair of the Steering Committee of the Center for Biomedical Ethics and the Director of the Stanford Program in Neuroscience and Society at Stanford Law School.",
    "is_supporting": false,
    "idx": 18,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nHenry T. \"Hank\" Greely is an American lawyer, a leading authority on the ethical, legal, and social implications of new biomedical technologies, particularly those related to genetics, assisted reproduction, neuroscience and stem cell research. [1]  Greely is the Deane F. and Kate Edelman Johnson Professor of Law, the     Director of the Center for Law and the Biosciences, the Genetics Chair of the Steering Committee of the Center for Biomedical Ethics and the Director of the Stanford Program in Neuroscience and Society at Stanford Law School.",
    "paragraph_text": "Introduction\nHenry T. \"Hank\" Greely is an American lawyer, a leading authority on the ethical, legal, and social implications of new biomedical technologies, particularly those related to genetics, assisted reproduction, neuroscience and stem cell research. [1]  Greely is the Deane F. and Kate Edelman Johnson Professor of Law, the     Director of the Center for Law and the Biosciences, the Genetics Chair of the Steering Committee of the Center for Biomedical Ethics and the Director of the Stanford Program in Neuroscience and Society at Stanford Law School."
  },
  {
    "title": "Eric Manvers Shooter",
    "content": "Introduction\nEric Manvers Shooter (born 18 April 1924 in Nottinghamshire, England;[1] died 21 March 2018) was an English scientist known for investigating the biochemistry of nerve growth factor (NGF). [2] From 1961 onwards he was affiliated with Stanford University School of Medicine, where he was founding chairman of the Department of Neurobiology (1975-1987).",
    "is_supporting": false,
    "idx": 19,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nEric Manvers Shooter (born 18 April 1924 in Nottinghamshire, England;[1] died 21 March 2018) was an English scientist known for investigating the biochemistry of nerve growth factor (NGF). [2] From 1961 onwards he was affiliated with Stanford University School of Medicine, where he was founding chairman of the Department of Neurobiology (1975-1987).",
    "paragraph_text": "Introduction\nEric Manvers Shooter (born 18 April 1924 in Nottinghamshire, England;[1] died 21 March 2018) was an English scientist known for investigating the biochemistry of nerve growth factor (NGF). [2] From 1961 onwards he was affiliated with Stanford University School of Medicine, where he was founding chairman of the Department of Neurobiology (1975-1987)."
  },
  {
    "title": "Richard Tsien",
    "content": "Introduction\nRichard Winyu Tsien (born 3 March 1945), is a Chinese-born American electrical engineer and neurobiologist. He is the Druckenmiller Professor of Neuroscience, Chair of the Department of Physiology and Neuroscience, and Director of the NYU Neuroscience Institute at New York University Medical Center,[3] and also an emeritus faculty member of Stanford University School of Medicine.",
    "is_supporting": false,
    "idx": 20,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nRichard Winyu Tsien (born 3 March 1945), is a Chinese-born American electrical engineer and neurobiologist. He is the Druckenmiller Professor of Neuroscience, Chair of the Department of Physiology and Neuroscience, and Director of the NYU Neuroscience Institute at New York University Medical Center,[3] and also an emeritus faculty member of Stanford University School of Medicine.",
    "paragraph_text": "Introduction\nRichard Winyu Tsien (born 3 March 1945), is a Chinese-born American electrical engineer and neurobiologist. He is the Druckenmiller Professor of Neuroscience, Chair of the Department of Physiology and Neuroscience, and Director of the NYU Neuroscience Institute at New York University Medical Center,[3] and also an emeritus faculty member of Stanford University School of Medicine."
  },
  {
    "title": "Denis Baylor",
    "content": "Introduction\nDenis Aristide Baylor (January 30, 1940 - March 16, 2022) was an American neurobiologist. He was professor emeritus of neurobiology at Stanford University.",
    "is_supporting": false,
    "idx": 21,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nDenis Aristide Baylor (January 30, 1940 - March 16, 2022) was an American neurobiologist. He was professor emeritus of neurobiology at Stanford University.",
    "paragraph_text": "Introduction\nDenis Aristide Baylor (January 30, 1940 - March 16, 2022) was an American neurobiologist. He was professor emeritus of neurobiology at Stanford University."
  },
  {
    "title": "Andrew D. Huberman",
    "content": "Introduction\nAndrew David Huberman (born September 26, 1975) is an American neuroscientist and podcaster. He is an associate professor of neurobiology and ophthalmology at the Stanford University School of Medicine. Since 2021, he has hosted the Huberman Lab podcast, which has been described as \"one of the most popular podcasts in the world\",[2] but has attracted criticism for promoting poorly supported health claims.",
    "is_supporting": false,
    "idx": 22,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nAndrew David Huberman (born September 26, 1975) is an American neuroscientist and podcaster. He is an associate professor of neurobiology and ophthalmology at the Stanford University School of Medicine. Since 2021, he has hosted the Huberman Lab podcast, which has been described as \"one of the most popular podcasts in the world\",[2] but has attracted criticism for promoting poorly supported health claims.",
    "paragraph_text": "Introduction\nAndrew David Huberman (born September 26, 1975) is an American neuroscientist and podcaster. He is an associate professor of neurobiology and ophthalmology at the Stanford University School of Medicine. Since 2021, he has hosted the Huberman Lab podcast, which has been described as \"one of the most popular podcasts in the world\",[2] but has attracted criticism for promoting poorly supported health claims."
  },
  {
    "title": "Brian Knutson",
    "content": "Introduction\nBrian Knutson is a professor of psychology and neuroscience at Stanford University and director of the Symbiotic Project on Affective Neuroscience. His research focuses on the neural basis of emotion, and has been covered in multiple news sources.",
    "is_supporting": false,
    "idx": 23,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nBrian Knutson is a professor of psychology and neuroscience at Stanford University and director of the Symbiotic Project on Affective Neuroscience. His research focuses on the neural basis of emotion, and has been covered in multiple news sources.",
    "paragraph_text": "Introduction\nBrian Knutson is a professor of psychology and neuroscience at Stanford University and director of the Symbiotic Project on Affective Neuroscience. His research focuses on the neural basis of emotion, and has been covered in multiple news sources."
  },
  {
    "title": "Giovanna Mallucci",
    "content": "Work with MRC\n\"The drug blocks a natural defense mechanism in cells which is overactive in the brains of people with frontotemporal dementia, Alzheimer's disease and Parkinson's, so has the potential to work for several conditions. So far it has only been tested in mice with frontotemporal dementia[12] but Alzheimer's Society is now funding the researchers to test it in models of Alzheimer's too.\"",
    "is_supporting": false,
    "idx": 24,
    "question_id": "case_study_university/question_1.json",
    "text": "Work with MRC\n\"The drug blocks a natural defense mechanism in cells which is overactive in the brains of people with frontotemporal dementia, Alzheimer's disease and Parkinson's, so has the potential to work for several conditions. So far it has only been tested in mice with frontotemporal dementia[12] but Alzheimer's Society is now funding the researchers to test it in models of Alzheimer's too.\"",
    "paragraph_text": "Work with MRC\n\"The drug blocks a natural defense mechanism in cells which is overactive in the brains of people with frontotemporal dementia, Alzheimer's disease and Parkinson's, so has the potential to work for several conditions. So far it has only been tested in mice with frontotemporal dementia[12] but Alzheimer's Society is now funding the researchers to test it in models of Alzheimer's too.\""
  },
  {
    "title": "Karen Ashe",
    "content": "Honors and awards\nAshe was awarded the Metlife Foundation Award for Medical Research in Alzheimer's Disease in 2005. [26] Ashe also earned the Potamkin Prize in 2006 for her Alzheimer's research,[27][28] shortly after the publication of the 2006 Nature paper.",
    "is_supporting": false,
    "idx": 25,
    "question_id": "case_study_university/question_1.json",
    "text": "Honors and awards\nAshe was awarded the Metlife Foundation Award for Medical Research in Alzheimer's Disease in 2005. [26] Ashe also earned the Potamkin Prize in 2006 for her Alzheimer's research,[27][28] shortly after the publication of the 2006 Nature paper.",
    "paragraph_text": "Honors and awards\nAshe was awarded the Metlife Foundation Award for Medical Research in Alzheimer's Disease in 2005. [26] Ashe also earned the Potamkin Prize in 2006 for her Alzheimer's research,[27][28] shortly after the publication of the 2006 Nature paper."
  },
  {
    "title": "Michael I. Miller",
    "content": "Neurodegeneration in brain mapping\nMiller and John Csernansky developed a long-term research effort on neuroanatomical phenotyping of Alzheimer's disease, Schizophrenia and mood disorder. In 2005, they published with John Morris an early work on predicting conversion to Alzheimer's disease based on clinically available MRI measurements using diffeomorphometry technologies.",
    "is_supporting": false,
    "idx": 26,
    "question_id": "case_study_university/question_1.json",
    "text": "Neurodegeneration in brain mapping\nMiller and John Csernansky developed a long-term research effort on neuroanatomical phenotyping of Alzheimer's disease, Schizophrenia and mood disorder. In 2005, they published with John Morris an early work on predicting conversion to Alzheimer's disease based on clinically available MRI measurements using diffeomorphometry technologies.",
    "paragraph_text": "Neurodegeneration in brain mapping\nMiller and John Csernansky developed a long-term research effort on neuroanatomical phenotyping of Alzheimer's disease, Schizophrenia and mood disorder. In 2005, they published with John Morris an early work on predicting conversion to Alzheimer's disease based on clinically available MRI measurements using diffeomorphometry technologies."
  },
  {
    "title": "Michela Gallagher",
    "content": "Research\n[28][29] For this work Gallagher received the Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery from the Alzheimer's Drug Discovery Foundation. [10] In addition, the company is studying a drug called GABA-A a5 PAM, which also targets hyperactivity in the hippocampus.",
    "is_supporting": false,
    "idx": 27,
    "question_id": "case_study_university/question_1.json",
    "text": "Research\n[28][29] For this work Gallagher received the Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery from the Alzheimer's Drug Discovery Foundation. [10] In addition, the company is studying a drug called GABA-A a5 PAM, which also targets hyperactivity in the hippocampus.",
    "paragraph_text": "Research\n[28][29] For this work Gallagher received the Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery from the Alzheimer's Drug Discovery Foundation. [10] In addition, the company is studying a drug called GABA-A a5 PAM, which also targets hyperactivity in the hippocampus."
  },
  {
    "title": "Susan Curtiss",
    "content": "Modularity\n[24][23] These cases serve as evidence supporting Curtiss's commitment to the modularity of syntactic and semantic faculties. In addition to her research on children who dissociate various language faculties, Curtiss researched the language of elderly adults with Alzheimer's disease and compared the results to that of elderly adults with unimpaired mental status. The 1987 study was titled Syntactic Preservation in Alzheimer's Disease.",
    "is_supporting": false,
    "idx": 28,
    "question_id": "case_study_university/question_1.json",
    "text": "Modularity\n[24][23] These cases serve as evidence supporting Curtiss's commitment to the modularity of syntactic and semantic faculties. In addition to her research on children who dissociate various language faculties, Curtiss researched the language of elderly adults with Alzheimer's disease and compared the results to that of elderly adults with unimpaired mental status. The 1987 study was titled Syntactic Preservation in Alzheimer's Disease.",
    "paragraph_text": "Modularity\n[24][23] These cases serve as evidence supporting Curtiss's commitment to the modularity of syntactic and semantic faculties. In addition to her research on children who dissociate various language faculties, Curtiss researched the language of elderly adults with Alzheimer's disease and compared the results to that of elderly adults with unimpaired mental status. The 1987 study was titled Syntactic Preservation in Alzheimer's Disease."
  },
  {
    "title": "Gerard D. Schellenberg",
    "content": "Research and career\n[2]  While at Washington, he was the senior author of a Science article locating the gene and mutations responsible for Werner syndrome, a form of progeria. His neurodegenerative disease research contributed to identification of genes implicated in Alzheimer's disease, including the presenilin 1 and presenilin 2 genes linked to early-onset AD,[3][4]  the RecQ helicase gene (WRN) which causes Werner's Syndrome,[5][6] the MAPT mutations which cause FTLD-tau type,[7] and subsequently the MAPT association with Guam amyotrophic lateral sclerosis/Parkinson dementia complex[8] and Alzheimer's Disease. [9]  He was awarded the Potamkin Prize for Alzheimer's Disease Research from the American Academy of Neurology in 1994,[10] the Metropolitan Life Foundation Award for Medical Research in 1995,[1] and was an Alzheimer's Association Medical Honoree in 1996.",
    "is_supporting": false,
    "idx": 29,
    "question_id": "case_study_university/question_1.json",
    "text": "Research and career\n[2]  While at Washington, he was the senior author of a Science article locating the gene and mutations responsible for Werner syndrome, a form of progeria. His neurodegenerative disease research contributed to identification of genes implicated in Alzheimer's disease, including the presenilin 1 and presenilin 2 genes linked to early-onset AD,[3][4]  the RecQ helicase gene (WRN) which causes Werner's Syndrome,[5][6] the MAPT mutations which cause FTLD-tau type,[7] and subsequently the MAPT association with Guam amyotrophic lateral sclerosis/Parkinson dementia complex[8] and Alzheimer's Disease. [9]  He was awarded the Potamkin Prize for Alzheimer's Disease Research from the American Academy of Neurology in 1994,[10] the Metropolitan Life Foundation Award for Medical Research in 1995,[1] and was an Alzheimer's Association Medical Honoree in 1996.",
    "paragraph_text": "Research and career\n[2]  While at Washington, he was the senior author of a Science article locating the gene and mutations responsible for Werner syndrome, a form of progeria. His neurodegenerative disease research contributed to identification of genes implicated in Alzheimer's disease, including the presenilin 1 and presenilin 2 genes linked to early-onset AD,[3][4]  the RecQ helicase gene (WRN) which causes Werner's Syndrome,[5][6] the MAPT mutations which cause FTLD-tau type,[7] and subsequently the MAPT association with Guam amyotrophic lateral sclerosis/Parkinson dementia complex[8] and Alzheimer's Disease. [9]  He was awarded the Potamkin Prize for Alzheimer's Disease Research from the American Academy of Neurology in 1994,[10] the Metropolitan Life Foundation Award for Medical Research in 1995,[1] and was an Alzheimer's Association Medical Honoree in 1996."
  },
  {
    "title": "Judes Poirier",
    "content": "Significant contributions\nDr. Poirier has made some key contributions to the advancement of scientific research on Alzheimer's and Parkinson's diseases. He belongs to a short list of Canadian scientists who made milestone discoveries in Canadian Health Research history. [1]  He is internationally renowned for his works on the role of apolipoprotein E in the normal and injured brain and, in the genetics of Alzheimer's disease.",
    "is_supporting": false,
    "idx": 30,
    "question_id": "case_study_university/question_1.json",
    "text": "Significant contributions\nDr. Poirier has made some key contributions to the advancement of scientific research on Alzheimer's and Parkinson's diseases. He belongs to a short list of Canadian scientists who made milestone discoveries in Canadian Health Research history. [1]  He is internationally renowned for his works on the role of apolipoprotein E in the normal and injured brain and, in the genetics of Alzheimer's disease.",
    "paragraph_text": "Significant contributions\nDr. Poirier has made some key contributions to the advancement of scientific research on Alzheimer's and Parkinson's diseases. He belongs to a short list of Canadian scientists who made milestone discoveries in Canadian Health Research history. [1]  He is internationally renowned for his works on the role of apolipoprotein E in the normal and injured brain and, in the genetics of Alzheimer's disease."
  },
  {
    "title": "Eva Feldman",
    "content": "Brain health and Alzheimer's disease\nbad fats on memory, as well as how gut health affects nerve function in both the brain and peripheral nerves. Using the knowledge gained from her ALS stem-cell research, Feldman is developing a similar stem-cell therapy for Alzheimer's disease, which, if approved, would be the first in-human clinical trial of its kind in medical history.",
    "is_supporting": false,
    "idx": 31,
    "question_id": "case_study_university/question_1.json",
    "text": "Brain health and Alzheimer's disease\nbad fats on memory, as well as how gut health affects nerve function in both the brain and peripheral nerves. Using the knowledge gained from her ALS stem-cell research, Feldman is developing a similar stem-cell therapy for Alzheimer's disease, which, if approved, would be the first in-human clinical trial of its kind in medical history.",
    "paragraph_text": "Brain health and Alzheimer's disease\nbad fats on memory, as well as how gut health affects nerve function in both the brain and peripheral nerves. Using the knowledge gained from her ALS stem-cell research, Feldman is developing a similar stem-cell therapy for Alzheimer's disease, which, if approved, would be the first in-human clinical trial of its kind in medical history."
  },
  {
    "title": "Manolis Kellis",
    "content": "Alzheimer's disease\nKellis, Li-Huei Tsai, and others at MIT used epigenomic markings in human and mouse brains to study the mechanisms leading to Alzheimer's disease, published in Nature in 2015. [20] They showed that immune cell activation and inflammation, which have long been associated with the condition, are not simply the result of neurodegeneration, as some researchers have argued.",
    "is_supporting": false,
    "idx": 32,
    "question_id": "case_study_university/question_1.json",
    "text": "Alzheimer's disease\nKellis, Li-Huei Tsai, and others at MIT used epigenomic markings in human and mouse brains to study the mechanisms leading to Alzheimer's disease, published in Nature in 2015. [20] They showed that immune cell activation and inflammation, which have long been associated with the condition, are not simply the result of neurodegeneration, as some researchers have argued.",
    "paragraph_text": "Alzheimer's disease\nKellis, Li-Huei Tsai, and others at MIT used epigenomic markings in human and mouse brains to study the mechanisms leading to Alzheimer's disease, published in Nature in 2015. [20] They showed that immune cell activation and inflammation, which have long been associated with the condition, are not simply the result of neurodegeneration, as some researchers have argued."
  },
  {
    "title": "Mathias Jucker",
    "content": "Introduction\nJucker is known for his research on the basic biologic mechanisms underlying brain aging and Alzheimer's disease. [9]",
    "is_supporting": false,
    "idx": 33,
    "question_id": "case_study_university/question_1.json",
    "text": "Introduction\nJucker is known for his research on the basic biologic mechanisms underlying brain aging and Alzheimer's disease. [9]",
    "paragraph_text": "Introduction\nJucker is known for his research on the basic biologic mechanisms underlying brain aging and Alzheimer's disease. [9]"
  },
  {
    "title": "Mathias Jucker",
    "content": "Awards\nJucker has received the Research Prize of the Swiss Alzheimer Association (2001),[1] the Zenith Fellows Award of the Alzheimer's Association (2006),[2] the Soriano Lectureship of the American Neurological Association (2010),[3] the Hamburg Science Award for dementia research[4][5] from the Academy of Sciences and Humanities in Hamburg (2013), the Metlife Foundation Award for Medical Research in Alzheimer's Disease (2014),[6][7] and the International Prize for Translational Neuroscience of the Gertrud Reemtsma Foundation (Max-Planck-Gesellschaft) (2020). [8]",
    "is_supporting": false,
    "idx": 34,
    "question_id": "case_study_university/question_1.json",
    "text": "Awards\nJucker has received the Research Prize of the Swiss Alzheimer Association (2001),[1] the Zenith Fellows Award of the Alzheimer's Association (2006),[2] the Soriano Lectureship of the American Neurological Association (2010),[3] the Hamburg Science Award for dementia research[4][5] from the Academy of Sciences and Humanities in Hamburg (2013), the Metlife Foundation Award for Medical Research in Alzheimer's Disease (2014),[6][7] and the International Prize for Translational Neuroscience of the Gertrud Reemtsma Foundation (Max-Planck-Gesellschaft) (2020). [8]",
    "paragraph_text": "Awards\nJucker has received the Research Prize of the Swiss Alzheimer Association (2001),[1] the Zenith Fellows Award of the Alzheimer's Association (2006),[2] the Soriano Lectureship of the American Neurological Association (2010),[3] the Hamburg Science Award for dementia research[4][5] from the Academy of Sciences and Humanities in Hamburg (2013), the Metlife Foundation Award for Medical Research in Alzheimer's Disease (2014),[6][7] and the International Prize for Translational Neuroscience of the Gertrud Reemtsma Foundation (Max-Planck-Gesellschaft) (2020). [8]"
  },
  {
    "title": "Tara Spires-Jones",
    "content": "Research\nSpires-Jones' research focuses on mechanisms of neurodegeneration in diseases that cause dementia, other neurodegenerative diseases, and ageing. [15]  She focuses specifically on the degeneration of synapse connections between neuronal braincells in Alzheimer's disease. She made the important discovery that soluble forms of amyloid beta and tau proteins that accumulate in neuropathological lesions in Alzheimer's disease both accumulate within synapses where they contribute to degeneration and cognitive decline.",
    "is_supporting": false,
    "idx": 35,
    "question_id": "case_study_university/question_1.json",
    "text": "Research\nSpires-Jones' research focuses on mechanisms of neurodegeneration in diseases that cause dementia, other neurodegenerative diseases, and ageing. [15]  She focuses specifically on the degeneration of synapse connections between neuronal braincells in Alzheimer's disease. She made the important discovery that soluble forms of amyloid beta and tau proteins that accumulate in neuropathological lesions in Alzheimer's disease both accumulate within synapses where they contribute to degeneration and cognitive decline.",
    "paragraph_text": "Research\nSpires-Jones' research focuses on mechanisms of neurodegeneration in diseases that cause dementia, other neurodegenerative diseases, and ageing. [15]  She focuses specifically on the degeneration of synapse connections between neuronal braincells in Alzheimer's disease. She made the important discovery that soluble forms of amyloid beta and tau proteins that accumulate in neuropathological lesions in Alzheimer's disease both accumulate within synapses where they contribute to degeneration and cognitive decline."
  },
  {
    "title": "Thomas C. Sudhof",
    "content": "Career and research\nThe project aims to drastically advance our understanding of neurological disorders. He also serves on the Research Consortium of Cure Alzheimer's Fund.",
    "is_supporting": false,
    "idx": 36,
    "question_id": "case_study_university/question_1.json",
    "text": "Career and research\nThe project aims to drastically advance our understanding of neurological disorders. He also serves on the Research Consortium of Cure Alzheimer's Fund.",
    "paragraph_text": "Career and research\nThe project aims to drastically advance our understanding of neurological disorders. He also serves on the Research Consortium of Cure Alzheimer's Fund."
  },
  {
    "title": "Tara Spires-Jones",
    "content": "Research\n[18]  She has several collaborations with industry, one of which has contributed to a clinical trial of a drug to remove amyloid beta from synapses in Alzheimer's disease. [19]  The spread of tau pathology through the brain in Alzheimer's disease correlates strongly with cognitive symptoms, and weherever tau pathology appears in the brain, neuron death occurs. Spires-Jones discovered that in addition to accumulating within synapses, tau spreads trans-synaptically through neural circuits.",
    "is_supporting": false,
    "idx": 37,
    "question_id": "case_study_university/question_1.json",
    "text": "Research\n[18]  She has several collaborations with industry, one of which has contributed to a clinical trial of a drug to remove amyloid beta from synapses in Alzheimer's disease. [19]  The spread of tau pathology through the brain in Alzheimer's disease correlates strongly with cognitive symptoms, and weherever tau pathology appears in the brain, neuron death occurs. Spires-Jones discovered that in addition to accumulating within synapses, tau spreads trans-synaptically through neural circuits.",
    "paragraph_text": "Research\n[18]  She has several collaborations with industry, one of which has contributed to a clinical trial of a drug to remove amyloid beta from synapses in Alzheimer's disease. [19]  The spread of tau pathology through the brain in Alzheimer's disease correlates strongly with cognitive symptoms, and weherever tau pathology appears in the brain, neuron death occurs. Spires-Jones discovered that in addition to accumulating within synapses, tau spreads trans-synaptically through neural circuits."
  },
  {
    "title": "Dena Dubal",
    "content": "Research and career\nShe demonstrated this by monitoring for the well-known Alzheimer's disease risk factors Apolipoprotein E (APOE) e4. [15] Dubal revealed that patients with the genetic variant APOE e4 have biomarkers of Alzheimer's disease, even before experiencing symptoms, whilst patients with APOE e4 and Klotho do not have these biomarkers. [15]  Dubal has identified a biological mechanism - an epigenetic change on the X chromosome - that may give rise to why women live longer.",
    "is_supporting": false,
    "idx": 38,
    "question_id": "case_study_university/question_1.json",
    "text": "Research and career\nShe demonstrated this by monitoring for the well-known Alzheimer's disease risk factors Apolipoprotein E (APOE) e4. [15] Dubal revealed that patients with the genetic variant APOE e4 have biomarkers of Alzheimer's disease, even before experiencing symptoms, whilst patients with APOE e4 and Klotho do not have these biomarkers. [15]  Dubal has identified a biological mechanism - an epigenetic change on the X chromosome - that may give rise to why women live longer.",
    "paragraph_text": "Research and career\nShe demonstrated this by monitoring for the well-known Alzheimer's disease risk factors Apolipoprotein E (APOE) e4. [15] Dubal revealed that patients with the genetic variant APOE e4 have biomarkers of Alzheimer's disease, even before experiencing symptoms, whilst patients with APOE e4 and Klotho do not have these biomarkers. [15]  Dubal has identified a biological mechanism - an epigenetic change on the X chromosome - that may give rise to why women live longer."
  },
  {
    "title": "Gerard D. Schellenberg",
    "content": "Research and career\n[1] In 2004, the National Institute on Aging awarded him an R37 Merit Award for Genomic Analysis of Alzheimer's Disease. [1]",
    "is_supporting": false,
    "idx": 39,
    "question_id": "case_study_university/question_1.json",
    "text": "Research and career\n[1] In 2004, the National Institute on Aging awarded him an R37 Merit Award for Genomic Analysis of Alzheimer's Disease. [1]",
    "paragraph_text": "Research and career\n[1] In 2004, the National Institute on Aging awarded him an R37 Merit Award for Genomic Analysis of Alzheimer's Disease. [1]"
  },
  {
    "title": "Barbara J. Sahakian",
    "content": "Career\n[9]  In her research, Sahakian uses techniques such as psychopharmacological, neuropsychological and neuroimaging (fMRI and PET). Key research areas for her group are Alzheimer's disease, Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), substance abuse, depression and mania. [4][5]  In 2007, Sahakian raised concerns regarding the ethics of using drugs intended to help dementia and Alzheimer's patients to instead enhance cognitive function in healthy people.",
    "is_supporting": false,
    "idx": 40,
    "question_id": "case_study_university/question_1.json",
    "text": "Career\n[9]  In her research, Sahakian uses techniques such as psychopharmacological, neuropsychological and neuroimaging (fMRI and PET). Key research areas for her group are Alzheimer's disease, Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), substance abuse, depression and mania. [4][5]  In 2007, Sahakian raised concerns regarding the ethics of using drugs intended to help dementia and Alzheimer's patients to instead enhance cognitive function in healthy people.",
    "paragraph_text": "Career\n[9]  In her research, Sahakian uses techniques such as psychopharmacological, neuropsychological and neuroimaging (fMRI and PET). Key research areas for her group are Alzheimer's disease, Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), substance abuse, depression and mania. [4][5]  In 2007, Sahakian raised concerns regarding the ethics of using drugs intended to help dementia and Alzheimer's patients to instead enhance cognitive function in healthy people."
  },
  {
    "title": "Anne B. Young",
    "content": "Harvard Medical School\nHer research has been in metabotropic glutamate receptors in neurodegeneration and Alzheimer's disease. In 2004, she mentored a student project about the gene for Huntington's Disease, which codes for the protein huntingtin.",
    "is_supporting": false,
    "idx": 41,
    "question_id": "case_study_university/question_1.json",
    "text": "Harvard Medical School\nHer research has been in metabotropic glutamate receptors in neurodegeneration and Alzheimer's disease. In 2004, she mentored a student project about the gene for Huntington's Disease, which codes for the protein huntingtin.",
    "paragraph_text": "Harvard Medical School\nHer research has been in metabotropic glutamate receptors in neurodegeneration and Alzheimer's disease. In 2004, she mentored a student project about the gene for Huntington's Disease, which codes for the protein huntingtin."
  },
  {
    "title": "Nozomi Nishimura",
    "content": "Research and career\nFor example, Nishimura demonstrated that in mouse models of Alzheimer's disease impeded blood flow in the brain due to neutrophils plugging capillaries, impacting total blood flow. [8]",
    "is_supporting": false,
    "idx": 42,
    "question_id": "case_study_university/question_1.json",
    "text": "Research and career\nFor example, Nishimura demonstrated that in mouse models of Alzheimer's disease impeded blood flow in the brain due to neutrophils plugging capillaries, impacting total blood flow. [8]",
    "paragraph_text": "Research and career\nFor example, Nishimura demonstrated that in mouse models of Alzheimer's disease impeded blood flow in the brain due to neutrophils plugging capillaries, impacting total blood flow. [8]"
  }
]